<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374708</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HD087712-01A1</org_study_id>
    <nct_id>NCT04374708</nct_id>
  </id_info>
  <brief_title>Gender Identity and Own Body Perception</brief_title>
  <official_title>Gender Identity and Own Body Perception- Implications for the Neurobiology of Gender Dysphoria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide valuable information on the neurobiological underpinning of gender&#xD;
      dysphoria (GD) and the effects of sex hormones, and promises to uncover functional or&#xD;
      structural neural patterns that could predict outcome in terms of body image and quality of&#xD;
      life after cross-sex hormone treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to understand the neurobiology of gender dysphoria (GD) and the&#xD;
      interactions between cross hormone treatment, the brain, and the body phenotype. The&#xD;
      investigators also aim to identify pre-treatment neurobiological and other factors to help&#xD;
      predict body congruence and quality of life outcomes from hormone treatment. There is&#xD;
      mounting interest in gender identity issues worldwide, as requests for gender-confirming&#xD;
      treatments have increased in the past 3 decades, and alarmingly high suicide rates have&#xD;
      recently been reported in those with GD. Despite this, little is known about neurobiological&#xD;
      or other etiological factors contributing to GD or gender incongruence. This study will&#xD;
      address a core feature of GD that has been little studied in terms of the neurobiology: the&#xD;
      incongruence between perception of self and one's own body.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cerebral networks measured by functional magnetic resonance imaging (fMRI) mediating body perception and association with subjective own-body self-incongruence</measure>
    <time_frame>Baseline Visit 2 pre hormone treatment</time_frame>
    <description>Own body perception in relation to functional and structural connection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morphometric differences by sex, gender identity and sexual orientation</measure>
    <time_frame>Baseline Visit 2 pre hormone treatment</time_frame>
    <description>Cortical thickness, surface area, cortical and subcortical structural volumes and white matter tracts measured by MRI in relation to sex and gender identity and sexual orientation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain activation during own body perception</measure>
    <time_frame>Baseline Visit 2 pre hormone treatment</time_frame>
    <description>Images of body morph test presented during fMRI scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cerebral networks measured by functional magnetic resonance imaging (fMRI) mediating body perception and association with subjective own-body self-incongruence</measure>
    <time_frame>Post hormone treatment. Visit 4 last appt. within 2 yrs of Visit 2.</time_frame>
    <description>Own body perception in relation to functional and structural connection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in morphometric differences by sex, gender identity and sexual orientation</measure>
    <time_frame>Post hormone treatment. Visit 4 last appt. within 2 yrs of Visit 2.</time_frame>
    <description>Cortical thickness, surface area, cortical and subcortical structural volumes and white matter tracts measured by MRI in relation to sex and gender identity and sexual orientation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in brain activation during own body perception</measure>
    <time_frame>Post hormone treatment. Visit 4 last appt. within 2 yrs of Visit 2.</time_frame>
    <description>Images of body morph test presented during fMRI scan</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gender Dysphoria</condition>
  <arm_group>
    <arm_group_label>trans men</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trans women</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>homosexual cisgender men</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>homosexual cisgender women</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cisgender women</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cisgender men</arm_group_label>
    <description>fMRI: body morph test and neurocognitive testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>fMRI</intervention_name>
    <description>fMRI: body morph test and neurocognitive testing</description>
    <arm_group_label>cisgender men</arm_group_label>
    <arm_group_label>cisgender women</arm_group_label>
    <arm_group_label>homosexual cisgender men</arm_group_label>
    <arm_group_label>homosexual cisgender women</arm_group_label>
    <arm_group_label>trans men</arm_group_label>
    <arm_group_label>trans women</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Investigators will enroll 150 participants between the ages of 18 and 40 (25 trans males;&#xD;
        25 trans females; 25 cis gender females; 25 cis gender males; 25 homosexual males; 25&#xD;
        homosexual females)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Participants with gender dysphoria (GD)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Females and males from any racial or ethnic background, between the ages of 18 years&#xD;
             and 40 years.&#xD;
&#xD;
          -  Participants must meet Diagnostic and Statistical Manual-5 criteria for GD (302.85)&#xD;
&#xD;
          -  Intelligence quotient (IQ) &gt; 80&#xD;
&#xD;
        Participants with GD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or on-going sex hormone medication&#xD;
&#xD;
          -  Previous sex reassignment surgery&#xD;
&#xD;
          -  Oral contraceptives&#xD;
&#xD;
          -  Participants with GD are not be taking any other psychotropic medication. (No&#xD;
             participant will be recommended to discontinue or taper medications for the purpose of&#xD;
             participating in the study.)&#xD;
&#xD;
          -  Irregular menstrual cycles&#xD;
&#xD;
        Control participants&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Females and males from any racial or ethnic background, between the ages of 18 and 40.&#xD;
&#xD;
          -  IQ &gt; 80&#xD;
&#xD;
        Control participants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric medications&#xD;
&#xD;
          -  A score of â‰¥ 1 standard deviation higher than population norms on the MADRS depression&#xD;
             or the Hamilton anxiety scale (HAMA)&#xD;
&#xD;
          -  Sex hormone treatment&#xD;
&#xD;
          -  Irregular menstrual cycles&#xD;
&#xD;
        Exclusion criteria for all participants:&#xD;
&#xD;
          -  Any known chromosomal or hormonal disorder&#xD;
&#xD;
          -  Current substance abuse or dependence&#xD;
&#xD;
          -  Current neurological disorder or psychiatric disorder&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current major medical disorders that may affect cerebral metabolism such as diabetes&#xD;
             or thyroid disorders&#xD;
&#xD;
          -  Head trauma associated with loss of consciousness&#xD;
&#xD;
          -  HIV positive individuals&#xD;
&#xD;
          -  Individuals with ferromagnetic metal implantations or devices. This includes any&#xD;
             electronic implants or devices, braces, infusion pumps, aneurysm clips, metal&#xD;
             fragments or foreign bodies, metal prostheses, joints, rods or plates&#xD;
&#xD;
          -  Visual acuity worse than 20/35 for each eye as determined by Snellen close vision&#xD;
             acuity chart. Acuity may be met with corrective lenses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Jamie Feusner</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Biobehavioral Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gender Dysphoria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

